Exelon4.6 mg/24 h (5 cm)

Exelon 4.6 mg/24 h (5 cm) is a cholinesterase inhibitor indicated for the treatment of the following conditions:

Established / FDA-approved uses

• Mild to moderate dementia of the Alzheimer's type (oral capsule, oral solution, and transdermal patch formulations).
• Mild to moderate dementia associated with Parkinson's disease (oral capsule, oral solution, and transdermal patch formulations).

Not established / off-label

Exelon 4.6 mg/24 h (5 cm) is not approved for severe Alzheimer's disease, vascular dementia, or other forms of cognitive impairment; use in these settings is not supported by robust evidence and is not recommended outside of specialist guidance.

Each capsule, oral solution, or transdermal patch contains Exelon 4.6 mg/24 h (5 cm) as the active pharmaceutical ingredient, equivalent to a specific strength of rivastigmine base. Common oral strengths include 1.5 mg, 3 mg, 4.5 mg, and 6 mg capsules, and 2 mg/mL oral solution. Transdermal patches are commonly available delivering 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours. Excipients vary by manufacturer and formulation.

Exelon 4.6 mg/24 h (5 cm) is a reversible, carbamate-type cholinesterase inhibitor that inhibits both acetylcholinesterase and butyrylcholinesterase enzymes in the central nervous system. By slowing the breakdown of acetylcholine, Exelon 4.6 mg/24 h (5 cm) increases cholinergic transmission, which is believed to underlie its beneficial effect on the cognitive and functional symptoms of Alzheimer's disease and Parkinson's disease dementia.

Exelon 4.6 mg/24 h (5 cm) is available as oral capsules, an oral solution, and a once-daily transdermal patch. The transdermal patch was developed to provide more continuous drug delivery and to reduce the gastrointestinal side effects commonly seen with oral dosing.

Exelon 4.6 mg/24 h (5 cm) belongs to the therapeutic class of cholinesterase inhibitors (anti-dementia agents), specifically a carbamate-derivative acetylcholinesterase and butyrylcholinesterase inhibitor used in the management of Alzheimer's disease and Parkinson's disease dementia.

Exelon 4.6 mg/24 h (5 cm) is a carbamate-type cholinesterase inhibitor that binds to and inactivates acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), the enzymes responsible for the breakdown of acetylcholine at cholinergic synapses. By inhibiting these enzymes, Exelon 4.6 mg/24 h (5 cm) increases the concentration and duration of action of acetylcholine, enhancing cholinergic neurotransmission in the brain, which is reduced in patients with Alzheimer's disease and Parkinson's disease dementia.

Pharmacokinetics: Exelon 4.6 mg/24 h (5 cm) is rapidly and completely absorbed after oral administration, undergoes extensive metabolism primarily via cholinesterase-mediated hydrolysis (largely independent of hepatic cytochrome P450 enzymes), and is excreted mainly via the kidneys. With the transdermal patch, absorption is slower and more sustained, providing more continuous plasma levels over 24 hours compared to oral dosing.

Oral Exelon 4.6 mg/24 h (5 cm) capsules and oral solution should be taken with food (breakfast and dinner) to reduce the likelihood of nausea and vomiting. The oral solution may be swallowed directly from the dosing syringe provided or mixed with a small glass of water, cold fruit juice, or soda.

The Exelon 4.6 mg/24 h (5 cm) transdermal patch should be applied to dry, intact skin on the back, upper arm, or chest once daily, with sites rotated to avoid skin irritation. Do not cut the patch. Wash hands after handling. Fold used patches in half with the adhesive side inward and dispose of safely, out of reach of children and pets.

Exelon 4.6 mg/24 h (5 cm) has the following well-established, clinically significant drug interactions:

• Other cholinergic agents / cholinomimetics: Concomitant use may produce additive cholinergic effects (e.g., excessive nausea, vomiting, bradycardia); avoid combining unless closely monitored.
• Anticholinergic drugs: Exelon 4.6 mg/24 h (5 cm) may interfere with (reduce) the activity of anticholinergic medications, potentially reducing their therapeutic effect.
• Succinylcholine-type neuromuscular blocking agents (used during anesthesia): Exelon 4.6 mg/24 h (5 cm), as a cholinesterase inhibitor, may exaggerate and prolong succinylcholine-induced muscle relaxation during surgery; inform anesthesia providers of Exelon 4.6 mg/24 h (5 cm) use before any surgical procedure.
• Beta-blockers: Concurrent use may have an additive effect leading to bradycardia, which could result in syncope; use with caution.
• NSAIDs: The cholinergic effects of Exelon 4.6 mg/24 h (5 cm) may increase gastric acid secretion; combined use with NSAIDs may increase the risk of gastrointestinal bleeding or ulceration.

The most commonly reported adverse effects of Exelon 4.6 mg/24 h (5 cm) are gastrointestinal and are more frequent with oral dosing and during dose titration:

• Very common: Nausea, vomiting, diarrhea, decreased appetite, and weight loss (can be clinically significant, particularly in patients with low body weight).
• Common: Dizziness, headache, abdominal pain, dyspepsia, fatigue, asthenia, insomnia, anxiety, tremor.
• With the transdermal patch: Application-site reactions such as erythema, itching, or dermatitis are common; severe or spreading skin reactions should prompt discontinuation and medical evaluation.
• Less common but clinically important: Bradycardia and other cardiac conduction effects, syncope, extrapyramidal symptoms (worsening of Parkinsonian symptoms), and rarely, seizures or severe cholinergic reactions.

Gastrointestinal effects are dose-related and can usually be minimized with slow titration and administration with food; persistent vomiting or signs of dehydration warrant prompt medical attention.

Pregnancy: There are limited human data on the use of Exelon 4.6 mg/24 h (5 cm) in pregnancy. Exelon 4.6 mg/24 h (5 cm) should be used during pregnancy only if clearly needed and the potential benefit to the mother justifies the potential risk to the fetus. Consult a physician before use if pregnant or planning pregnancy.

Lactation: It is not known whether Exelon 4.6 mg/24 h (5 cm) is excreted in human breast milk. Because many drugs are excreted in breast milk and the effects on a nursing infant are unknown, a decision should be made whether to discontinue breastfeeding or discontinue Exelon 4.6 mg/24 h (5 cm), taking into account the importance of the drug to the mother, in consultation with a physician.

Exelon 4.6 mg/24 h (5 cm) should be used with caution in the following situations:

• Cardiac conduction abnormalities / sick sinus syndrome: As a cholinergic agent, Exelon 4.6 mg/24 h (5 cm) may have vagotonic effects on heart rate (e.g., bradycardia), which may be hazardous in patients with sick sinus syndrome or other supraventricular cardiac conduction conditions.
• Active peptic ulcer disease or increased risk of gastrointestinal bleeding: Cholinesterase inhibitors can increase gastric acid secretion; monitor patients with a history of ulcer disease or those taking concurrent NSAIDs for signs of gastrointestinal bleeding.
• Asthma or obstructive pulmonary disease (e.g., COPD): Due to cholinergic effects that may cause bronchoconstriction, use Exelon 4.6 mg/24 h (5 cm) with caution in patients with these conditions.
• Genitourinary obstruction and seizure disorders: Cholinomimetics may cause bladder outflow obstruction and can theoretically influence seizure activity; use with caution.
• Body weight loss: Monitor body weight during treatment, particularly in patients with a low baseline weight, due to the risk of significant appetite and weight loss.
• Interrupted therapy: If treatment is stopped for more than a few days, restart at the lowest dose and re-titrate, as resuming at a previously tolerated dose can cause severe vomiting.
• Transdermal patch specific: Apply only one patch at a time; remove the old patch before applying a new one and rotate application sites to reduce the risk of accidental overdose and skin reactions.

Overdose with Exelon 4.6 mg/24 h (5 cm) may result in a cholinergic crisis with symptoms such as severe nausea, vomiting, diarrhea, excessive sweating, salivation, bradycardia, hypotension, respiratory depression, collapse, and seizures. Progressive muscle weakness is possible and may be life-threatening if respiratory muscles are involved.

In case of suspected overdose, seek immediate medical attention or contact a poison control center/emergency services right away. If the transdermal patch is involved, remove all patches from the skin immediately. Management is supportive and should be provided under medical supervision; atropine may be considered by treating physicians as an antidote for severe muscarinic symptoms. Do not attempt to manage a suspected overdose at home without professional medical guidance.

Store at room temperature (below 30°C), away from light and moisture. Keep transdermal patches in their sealed sachet until ready for use. Keep out of reach of children.

Renal impairment: No specific dose adjustment is generally required, but Exelon 4.6 mg/24 h (5 cm) should be titrated cautiously and patients monitored closely, as clearance may be reduced in significant renal impairment.

Hepatic impairment: Titrate Exelon 4.6 mg/24 h (5 cm) cautiously based on individual tolerability in patients with hepatic impairment.

Elderly: Exelon 4.6 mg/24 h (5 cm) is primarily used in an elderly population (Alzheimer's and Parkinson's disease dementia); no specific dose adjustment beyond standard titration is required based on age alone, but elderly patients should be monitored closely for gastrointestinal and cardiac adverse effects.

Pediatric: Safety and efficacy of Exelon 4.6 mg/24 h (5 cm) have not been established in children; it is not indicated for pediatric use.

Exelon 4.6 mg/24 h (5 cm) is typically used as a long-term, ongoing treatment for as long as it provides clinical benefit for Alzheimer's disease or Parkinson's disease dementia, as determined by the prescribing physician. Response and continued need for therapy should be periodically reassessed by the treating physician; do not stop or restart treatment abruptly without medical advice, as doing so may require re-titration from the lowest dose.

Exelon 4.6 mg/24 h (5 cm) is classified as a cholinesterase inhibitor (carbamate-type acetylcholinesterase and butyrylcholinesterase inhibitor), within the broader category of anti-dementia / anti-Alzheimer's agents.

Exelon 4.6 mg/24 h (5 cm) works by reversibly inhibiting acetylcholinesterase and butyrylcholinesterase, the enzymes that break down acetylcholine at cholinergic nerve synapses. This inhibition increases the availability of acetylcholine in the brain, enhancing cholinergic neurotransmission that is deficient in Alzheimer's disease and Parkinson's disease dementia, which helps improve cognitive and functional symptoms.

Category B

Exelon 4.6 mg/24 h (5 cm) is not approved for use in children or adolescents. Safety and efficacy in the pediatric population have not been established, and Exelon 4.6 mg/24 h (5 cm) should not be used in this age group outside of a clinical trial setting.